רפמיון 1 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

SIROLIMUS 1.00 MG

Disponible depuis:

NEOPHARM LTD

Code ATC:

L04AA10

forme pharmaceutique:

COATED TABLETS

Mode d'administration:

PER OS

Fabriqué par:

PFIZER IRELAND PHARMACEUTICALS

Groupe thérapeutique:

SIROLIMUS

indications thérapeutiques:

Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Date de l'autorisation:

2009-10-01